Châtillon, France, January 16, 2026DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of ...

DBV Technologies previously announced that it had raised €166.7 million in gross proceeds from the full exercise of warrants ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the virtual SBV Securities Global ...

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where DBV Technologies S.A. (NASDAQ:DBVT) stands against other ...

On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as ...

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology PEOPLE is the largest long-term peanut ...

DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently ...

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: ...